These subgroups were chosen for comparative analysis because ALK and ROS1 fusions are well‐validated fusion genes in lung adenocarcinoma, whereas EGFR mutations are a commonly validated driver gene primarily receiving targeted therapy. Here, EGFR is linked to lung adenocarcinoma.